• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Apoptosis in Oncology Drug Pipeline Update 2014 Product Image

Apoptosis in Oncology Drug Pipeline Update 2014

  • Published: March 2014
  • Region: Global
  • Bioseeker

Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells.
There are today 344 companies plus partners developing 412 apoptotic drugs in 1890 developmental projects in cancer. In addition, there are 9 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 213 drugs. Apoptosis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 301 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 292 out of the 294 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 63 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How READ MORE >

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos